Chimerix

Licensing Opportunities

Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology and the Chimerix Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines.

As our products demonstrate clinical proof-of-concept, we will seek out strategic collaborations and partnerships with pharmaceutical companies for late-stage clinical development and marketing.

For more information, please contact .(JavaScript must be enabled to view this email address).